− Vutrisiran, which Silences Transthyretin at the Source, Shown to Improve Health-Related Quality-of-Life in Those with ATTR-CM, with Treatment Effects Comparable to Patients More than Ten Years Younger...
− Efforts Aimed at Facilitating Earlier Diagnosis, Coordinated Care, and Long-Term Patient Impact in ATTR-CM – − Alnylam to Host TTR Investor Webinar Today at 9:30...
/Incyte%20Corp_%20office%20sign-by%20Bo%20Shen%20via%20iStock.jpg)
Incyte has outperformed the Dow over the past year, and analysts are moderately optimistic about the stock’s prospects.
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will webcast its upcoming TTR Investor Webinar on the Investors section of the Company’s...
Agreement Combines Tenaya’s Expertise in Identification and Validation of Genetic Heart Disease Targets with Alnylam’s Ability to Deliver Transformational Therapeutics Tenaya to Receive Up to...
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the TD Cowen 46 th Annual...
− Achieved Fourth Quarter and Full Year 2025 Global Net Product Revenues of $995 Million and $2,987 Million, Respectively, Representing 121% and 81% Growth Compared to Same Periods in 2024 – ...
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the fourth quarter and year ending December 31, 2025...
The S&P 500 Index ($SPX ) (SPY ) on Monday closed up +0.16%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed up +0.17%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed up +0.08%. March E-mini S&P...